key: cord-0921410-tcq1bwmg
authors: Roberts, J. Scott; Ferber, Rebecca; Blacker, Deborah; Rumbaugh, Malia; Grill, Joshua D.
title: Disclosure of individual research results at federally funded Alzheimer's Disease Research Centers
date: 2021-10-14
journal: Alzheimers Dement (N Y)
DOI: 10.1002/trc2.12213
sha: 4cb7eaf6c54d17fa47296ffbab3e4015d3cc316c
doc_id: 921410
cord_uid: tcq1bwmg

INTRODUCTION: This study describes practices for disclosing individual research results to participants in Alzheimer's disease research. METHODS: An online survey of clinical core leaders at National Institutes of Health‐funded Alzheimer's Disease Research Centers in the United States (response rate: 30/31, 97%) examined return of results practices across nine different types of research results. RESULTS: Most centers had returned consensus research diagnoses (83%) and neuropsychological test results (73%), with fewer having shared amyloid positron emission tomography (43%), tau imaging (10%), or apolipoprotein E (APOE) genotype (7%) results. Centers reported having disclosed a mean of 3.1 types of results (standard deviation = 2.1; range 0–8). The most commonly cited reason for disclosure was to inform participants’ medical decision‐making (88%). Disclosure involved multiple professionals and modalities, with neurologists (87%) and in‐person visits (85%) most commonplace. DISCUSSION: Centers varied widely as to whether and how they disclosed research results. Diagnostic and cognitive test results were more commonly returned than genetic or biomarker results.

report encouraging investigators to consider more frequent disclosure of research results to study participants, provided the results were reliable, valid, and of use and interest to participants. 3 Authors of the report contended that return of results was an important means of giving back to participants for their volunteer efforts and enhancing public trust and engagement in the research enterprise. Yet investigators are often reluctant to disclose research results to participants for a variety of reasons. For example, they may lack requisite financial and human resources for effectively conveying results to participants (e.g., health professionals with skills and expertise in disclosing sensitive results), they may fear potential legal liabilities brought on by disclosure, and they commonly collect data using procedures viewed as insufficiently reliable or valid for disclosure of clinically significant results. 4 This debate is particularly relevant in clinical research on Alzheimer's disease (AD) and related dementias, where individual-level data are routinely generated in areas of interest to patients and family members. For example, many clinical studies rigorously assess individuals' cognitive performance, produce consensus research diagnoses, and collect genetic and biomarker information. Oftentimes such information comes from cutting-edge technologies (e.g., investigational neuroimaging, genome sequencing) that would not typically be available in general clinical practice. For individuals with cognitive impairment, such information might be used to inform medical decision-making.

For asymptomatic individuals, dementia risk information via methods like apolipoprotein E (APOE) genotyping and amyloid neuroimaging is often of interest for a variety of reasons (e.g., advance planning, informing health behaviors that might reduce dementia risk), 5-7 even if such testing is not recommended in clinical practice. 8, 9 Studies of dementia research participants' preferences suggest high overall levels of interest in learning a range of individual research results, including genetic information and results from neuroimaging and cognitive testing. 10 Little is known about the extent to which dementia researchers disclose individual research results to study participants or how they share such results. Gauging researchers' current practices in this area would be an important step in understanding how best to address challenges posed by return of research results. A key stakeholder in this debate is the national network of Alzheimer's Disease Research Centers (ADRCs) in the United States, funded by the National Institute on Aging. Each of these centers is charged with creating a longitudinal cohort study in which they follow a sample of older adults both with and without cognitive impairment. Standardized assessments across a wide range of domains are conducted annually, with data pooled across sites at the National Alzheimer's Coordinating Center (NACC). We con- 

The study survey was initiated under the auspices of the Advisory Group on Risk Evidence Education for Dementia (AGREED), a national working group of dementia research professionals and advocates convened to facilitate responsible and effective communication of dementia risk information. 11 We created a survey to assess disclosure practices at National Institutes of Health-funded ADRCs in the United States (note: AGREED is led by three ADRC-affiliated investigators, and all but one of this paper's authors are affiliated with ADRCs). The survey was reviewed in multiple iterations by various subcommittees of the AGREED working group, which included dementia researchers, clinicians, policy experts, individuals with early-stage dementia, and research participants. The review process helped refine survey items (e.g., clarifying their wording and response choices, identifying additional survey topics), improve survey flow, and minimize respondent burden.

The survey was administered via Internet to all ADRCs that were actively funded at the time of data collection (N = 31). Invited respondents were clinical core leaders across sites, given that those investigators were responsible for the main longitudinal cohort study 

The primary focus of the survey was each center's general practices of disclosure of individual research results to participants in their longitudinal cohort study. Specifically, questions were anchored to results generated in the site's clinical core for its participants in the Uniform Data Set (UDS), a national database to which all ADRCs contribute. Survey items included: (1) types of research results disclosed, the types of participants to whom results were disclosed, and the frequency with which disclosure typically occurred; (2) reasons for and against disclosing research results; and (3) the process of disclosure, including professionals involved, modalities used, and elements of the disclosure process. The survey itself is provided in supporting information.

The survey asked a series of questions regarding disclosure of research results within their center's longitudinal cohort study. First, respondents were asked about the types of results that had been disclosed. 

For each type of research result for which disclosure had taken place, respondents were asked to indicate which of six potential reasons had prompted disclosure (e.g., result was potentially clinically useful, the participant had requested it; Table 2 ). For results for which disclosure had not taken place, respondents were asked to indicate which of eight potential reasons had prompted lack of disclosure (e.g., result was not clinically useful, potential for unintended harms; Table 3 ). For both sets of questions, respondents could write in "other" reasons why disclosure had or had not been offered. Follow-up questions were asked regarding potential reasons for or against disclosure of results. At sites where genetic information had been collected from research participants, respondents were asked whether genetic testing had occurred in a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory. All respondents were asked to indicate whether and how the longitudinal cohort study's informed consent form addressed return of results (e.g., it specified which results would be returned, it stated no results would be returned).

For all types of research results for which disclosure had occurred, respondents were asked to indicate which types of professionals had been involved in communicating results. Response choices included seven types of professionals (e.g., neurologist, psychologist, nurse; Table 4 ), along with an open-ended "other" item. For each type of result, respondents were also asked to indicate whether disclosure had taken place via an in-person visit, mailed letter, telephone, or an "other" modality (Table 4 ). Finally, respondents were asked about various aspects of the disclosure process, indicating whether seven specific features had been included (e.g., recommendations for next steps, resources for more information; Table 5 ).

Given the small sample size of ADRCs surveyed, descriptive statistics were used to characterize survey responses. Chi-square analyses were used to assess whether disclosure of research results differed by participant type, collapsing responses into those with dementia or MCI versus those with subjective memory complaints or normal cognition. 

ADRCs surveyed (Table 1) 

Centers endorsed a range of reasons for disclosing research results to participants ( 

A wide range of health professionals were involved in disclosure of research results (Table 4 ). Neurologists were by far the most commonly reported type of professional (87%), taking part in disclosure of all categories of results. Psychologists were the next most commonly mentioned group, cited in 30% of all types of disclosures and a majority (64%) of those involving neuropsychological test results.

Other professionals involved in disclosure included geriatric psychiatrists (22%), nurses/nurse practitioners (17%), geriatricians (16%), and research coordinators (12%). In the rare instances in which APOE genotype results were returned (n = 2 centers), genetic counselors were not reported as being involved in disclosure, although they were for disclosure of other types of genetic results (e.g., high penetrance pathogenic variants for familial AD).

Research results were disclosed in a variety of formats, with inperson visits being the most commonly used (85%). Telephone disclosure was reportedly used in half of all types of return of results (Table 4 ). Mailed letters were frequently used (38%), most commonly for neuropsychological test results but rarely for disclosure of genetic or biomarker results (e.g., only 1 of 13 ADRCs returning amyloid PET results).

There was considerable variation across centers regarding elements of the disclosure process (Table 5) . A majority of respondents indicated that return of research results at their site included recommendations for next steps (76%) and provision of resources for more information (55%). Fewer than half of types of results disclosure reportedly involved communication with participants' physicians (40%), provision of a take-home letter summarizing results (37%), and post-disclosure counseling (30%). Use of pre-disclosure education sessions (20%) and visual aids to assist communication of results (11%)

were relatively infrequently used.

This is the first study to systematically assess return of individual Finally, data collection took place prior to the onset of the COVID-19

pandemic, which has likely affected sites' ability and practices for disclosing research results.

There are several directions for future research on return of individual research in dementia-related studies. As noted above, an emerging body of literature has begun to assess the process and impact of disclosing genetic and biomarker risk information for AD and related dementias. Such work could be expanded in several ways. First, most studies to date have focused on APOE genotyping and amyloid neuroimaging, but other types of genetic and biomarker information are of potential interest, including polygenic risk scores, tau imaging, and blood-based biomarkers such as p-tau-217. 19 Within such studies, it would be helpful to examine the utility of different methods for reducing barriers to the communication of research results (e.g., use of telehealth modalities for disclosure, creation of centralized education resources and protocols to support return of results at ADRCs). Second, studies of the impact of results disclosure could examine a broader range of outcomes, beyond psychological and behavioral effects. For example, such studies have not typically assessed the economic costs of disclosure (even though financial barriers to return of results are commonly cited), or how return of results might enhance retention of participants in longitudinal studies, even though this and other studies suggest ADRCs view this as an important potential benefit. 20 In addition, the potential for results disclosure to bias cognitive outcomes being collected in ADRCs' longitudinal cohort studies could be further investigated, given preliminary findings that knowledge of APOE genotype could influence one's performance on objective and subjective measures of memory. 21 Finally, return of results studies could benefit from more diverse study samples, both in terms of race/ethnicity and socioeconomic status. Encouragingly, the National Institute on Aging has recently funded studies in this area that may help address some of these gaps in knowledge. 22 Such diversity would also be welcome more generally in AD research, given that the role of genetic factors and biomarkers in AD etiology may differ across populations.

This study was conducted with organizational support from the 

Return of results: ethical and legal distinctions between research and clinical care

Best practices for returning research findings to participants: methodological and ethical considerations for communication researchers

Returning Individual Research Results to Participants: Guidance for a New Research Paradigm

Return of genomic results to research participants: the floor, the ceiling, and the choices in between

A survey of knowledge and views concerning genetic and amyloid PET status disclosure

Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents

Public perceptions of presymptomatic testing for Alzheimer's disease

Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer's association

Genetic counseling and testing for Alzheimer's disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors

Attitudes of research participants and the general public regarding disclosure of Alzheimer's disease research results

The formation of the advisory group on risk evaluation education for dementia. Alzheimer's Dement

Ethical considerations in neurogenetic testing

Disclosure of APOE genotype for risk of Alzheimer's disease

Genetic testing for risk of Alzheimer's disease: benefit or burden?

Short-term psychological outcomes of disclosing amyloid imaging results to research participants who do not have cognitive impairment

A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment

Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results

A randomized controlled trial of disclosing genetic risk information for Alzheimer's disease via telephone

Genetic testing for neurodegenerative diseases: ethical and health communication challenges

Retention of Alzheimer's disease research participants

Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults

Communicating 5-year risk of Alzheimer's disease dementia: development and evaluation of materials that incorporate multiple genetic and biomarker research results

The authors thank Nina Silverberg, PhD of the National Institute on Aging for her assistance in study recruitment efforts, and the Clinical Core Leaders of the Alzheimer's Disease Research Centers for their survey participation.

The authors report no financial conflicts of interest. Dr. Roberts has served as a paid advisory board member for the national